Ignite Creation Date:
2025-12-24 @ 2:22 PM
Ignite Modification Date:
2026-01-01 @ 8:18 AM
Study NCT ID:
NCT04135495
Status:
COMPLETED
Last Update Posted:
2022-11-22
First Post:
2019-08-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
Sponsor:
Eloxx Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-25
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-03
Completion Date Type:
ACTUAL
First Submit Date:
2019-08-16
First Submit QC Date:
None
Study First Post Date:
2019-10-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-21
Last Update Post Date:
2022-11-22
Last Update Post Date Type:
ACTUAL